Spdr S&p Biotech Etf ETF News

Howard Capital Management Group LLC raised its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 4.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 185,569 shares of the exchange traded funds stock after purchasing an additional 7,465 []

Avantax Advisory Services Inc. raised its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.1% in the third quarter, HoldingsChannel.com reports. The firm owned 13,720 shares of the exchange traded funds stock after buying an additional 283 shares during the period. Avantax Advisory Services Inc.s holdings in SPDR S&P Biotech ETF were worth []

All three of these biotech stocks lost around half their value over the past few months.

The Zacks Analyst Blog Highlights: XMVM, VFH, XRT, XBI and SPVU

With the easing of Omicron fears, Wall Street jumped to start a new week after a broad market sell-off in the past couple of weeks.

Hanson & Doremus Investment Management increased its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 23.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,647 shares of the exchange traded fund’s stock after acquiring an additional 2,055 shares during the […]

These eight stocks could rebound nicely over the next year and beyond.

Cornell Pochily Investment Advisors Inc. bought a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the third quarter, Holdings Channel.com reports. The firm bought 2,292 shares of the exchange traded funds stock, valued at approximately $288,000. Other institutional investors and hedge funds also recently modified their holdings of the company. Chiron Capital Management LLC []

With the easing of Omicron fears, Wall Street jumped to start a new week after a broad market sell-off in the past couple of weeks.

SPDR S&P Biotech ETF (NYSEARCA:XBI) reached a new 52-week low during trading on Monday . The stock traded as low as $106.96 and last traded at $108.65, with a volume of 65802 shares traded. The stock had previously closed at $109.53. The firm has a fifty day moving average of $124.03 and a 200 day []

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms.

Pinnacle Associates Ltd. lifted its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,026 shares of the exchange traded funds stock after acquiring an additional 268 shares during the quarter. Pinnacle []

I had rated the SPDR S&P Biotech ETF as bullish in July 2020. The ETF's price spiked by 51% thereafter, and later, regressed to its mean. Historical data reveal that the ETF delivered solid price gain

Stratos Wealth Partners LTD. grew its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,513 shares of the exchange traded funds stock after acquiring an additional 366 shares during the quarter. Stratos Wealth Partners []